Remdesivir, used against Covid-19, has already earned Gilead nearly $ 900 million

The antiviral drug remdesivir, used for hospital patients with Covid-19, has already reported to its manufacturer Gilead Sciences nearly $ 900 million in the third quarter, the pharmaceutical company announced on Wednesday.

Read also: The United States fully authorizes the antiviral remdesivir against Covid-19

Thanks to sales of this product, initially developed in vain against Ebola hemorrhagic fever, the group saw its quarterly turnover increase in total by 17% to 6.58 billion dollars.